الصفحة الرئيسية>>Signaling Pathways>> Membrane Transporter/Ion Channel>> Proton Pump>>Rabeprazole

Rabeprazole

رقم الكتالوجGC16645

رابيبرازول (LY307640) هو من الجيل الثاني من مثبطات مضخة البروتون (PPI) الذي يعطل المعدة بشكل لا رجعة فيه H+ / K+-ATPase.

Products are for research use only. Not for human use. We do not sell to patients.

Rabeprazole التركيب الكيميائي

Cas No.: 117976-89-3

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
68٫00
متوفر
10mg
38٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Rabeprazole is an antiulcer drug in the class of proton pump inhibitors.Target: Proton PumpRabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H+/K+ATPase (hydrogen-potassium adenosine triphosphatase) at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton-pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion. In gastric parietal cells, rabeprazole is protonated, accumulates, and is transformed to an active sulfenamide. When studied in vitro, rabeprazole is chemically activated at pH 1.2 with a half-life of 78 seconds.

References:
[1]. http://www.drugbank.ca/drugs/DB01129

مراجعات

Review for Rabeprazole

Average Rating: 5 ★★★★★ (Based on Reviews and 26 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Rabeprazole

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.